Fidaxomicin (Dificlir®)

Assessment Status Assessment process complete
HTA ID -
Drug Fidaxomicin
Brand Dificlir®
Indication For the treatment of CDI also known as CDAD in adult patients. Rapid Review
Assessment Process
Rapid review commissioned 09/03/2012
Rapid review completed 23/03/2012
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended.
Full pharmacoeconomic assessment commissioned by HSE 05/12/2012
NCPE assessment completed 05/02/2013
NCPE assessment outcome Reimbursement recommended.

Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013 www.hpsc.ie).

 

Technical Summary